Navigation Links
Cornerstone Therapeutics to Present at Two Upcoming Investor Conferences
Date:9/3/2009

CARY, N.C., Sept. 3 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market, today announced that Craig A. Collard, President and Chief Executive Officer, will be presenting a corporate overview at two upcoming investor conferences.

Mr. Collard will first present at the Thomas Weisel Partners Healthcare Conference 2009 at 4:25 PM ET on Wednesday, September 9th, 2009, at the Four Seasons Hotel in Boston, MA. He will then deliver the Company's corporate overview at the Rodman & Renshaw 11th Annual Healthcare Conference at 9:10 AM ET on Thursday, September 10th, 2009, at the New York Palace Hotel in New York City. Both conferences will be held from September 9th - 11th, 2009.

Live audio and archived webcasts of Cornerstone's presentations will be available through the Investor Relations section of the Company's website.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory market; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

    Investor Relations Contacts:
    FD
    Evan Smith/Brian Ritchie
    212-850-5600
    evan.smith@fd.com/brian.ritchie@fd.com

    Media Relations Contact:
    FD
    Robert Stanislaro
    212-850-5600
    robert.stanislaro@fd.com


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
3. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
4. Cornerstone Therapeutics Announces New Board of Directors
5. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
6. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
7. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Cornerstone Therapeutics Announces Management Change
10. TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: